Kaufman Et Broad (KOF)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 19.00 |
|---|---|
| 52-week range | 18.40 – 30.44 |
| Return, 1 month / 3 months | −11.4% / −26.8% |
| Return, 1 year / 3 years | −28.8% / −4.7% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 23.4% |
| Worst drawdown (1 year) | -38.6% |
| Average daily value traded | 0.78M EUR |
| Dividend yield | 11.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kaufman Et Broad is a French property developer based in Paris that builds and sells new homes and apartment buildings, mainly in France. It develops residential schemes for individual buyers and for investors, and it also works on urban development projects and commercial property. Its activities cover land sourcing, construction and the marketing of completed homes, with customers ranging from first-time buyers to property investors.
On this site Kaufman Et Broad appears as a stock on the Euronext Paris (France), code KOF, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kaufman Et Broad (KOF) trades on the Euronext Paris in France. It last closed at EUR 19.00 on 19 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 363 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 28.8% and over the last three months it fell 26.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 26 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -24.9% | ||
| From 52-week high | -36.9% | ||
| Momentum | 23 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -26.8% | ||
| 6-month return | -27.6% | ||
| 12-month return, skipping the last month | -19.6% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 23.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.6% | ||
| Liquidity | 77 · Strong | Trades actively. | |
| Average daily value traded | 0.78M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 76 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 11.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +2.7% |
|---|---|
| 1 month | −11.4% |
| 3 months | −26.8% |
| 6 months | −27.6% |
| 1 year | −28.8% |
| 3 years | −4.7% |
| 5 years | −20.2% |
Signals
| 50-day / 200-day average | 21.95 / 25.29 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.49 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 May 2026 | EUR 2.2000 |
| 9 May 2025 | EUR 2.2000 |
| 7 May 2024 | EUR 2.4000 |
| 9 May 2023 | EUR 2.4000 |
| 1 Jun 2022 | EUR 1.9500 |
| 2 Jun 2021 | EUR 1.8500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.